Tafasitamab Plus Lenalidomide and Rituximab Improves Progression-Free Survival in Relapsed or Refractory Follicular Lymphoma

HEALTH News

Tafasitamab Plus Lenalidomide and Rituximab Improves Progression-Free Survival in Relapsed or Refractory Follicular Lymphoma
FOLOLICULAR LYMPHOMARelapsedREFRACTORY
  • 📰 Medscape
  • ⏱ Reading Time:
  • 75 sec. here
  • 9 min. at publisher
  • 📊 Quality Score:
  • News: 54%
  • Publisher: 55%

A phase 3 clinical trial demonstrates that adding tafasitamab to lenalidomide and rituximab significantly extends progression-free survival in patients with relapsed or refractory follicular lymphoma.

In the treatment of relapsed or refractory follicular lymphoma (R/R FL), the addition of tafasitamab to a standard 2-drug combination of lenalidomide and rituximab (len+R) significantly improves progression-free survival, with no increases in safety events. This study is the first to validate combining two monoclonal antibodies (anti-CD19 with anti-CD20) in the treatment of lymphoma, said first author Laurie H.

Sehn, MD, MPH, a clinical professor with the BC Cancer Centre for Lymphoid Cancer and the University of British Columbia in Vancouver, British Columbia, Canada. She presented the findings at the. Tafasitamab plus lenalidomide and rituximab can be administered in community as well as academic settings and represents a potential new standard-of-care option for patients with R/R follicular lymphoma, she noted. The results are from the international, phase 3 inMIND multicenter trial involving 548 patients with R/R FL, with a median age of 64. Of the patients, 45% had been treated with two or more prior lines of therapy. At a median follow up of 14.1 months, those randomized to treatment with tafasitamab and len+R (n=273) had a significantly lower risk for progression, relapse, or death than those receiving the double therapy with placebo (n=275), with a median progression-free survival of 22.4 months vs 13.9 months, respectively (hazard ratio , 0.43; Improved progression-free survival was observed across all prespecified subgroups, including patients with disease progression within 24 months, those who were refractory to prior anti-CD20 monoclonal antibodies, and who received multiple prior lines of therapy. Although this study was not powered for individual subgroups, it is clear that there’s a significant benefit of tafasitamab in all subgroups regardless of status of and regardless of refractoriness to prior anti-CD20 monoclonal antibodies,” Sehn noted

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Medscape /  🏆 386. in US

FOLOLICULAR LYMPHOMA Relapsed REFRACTORY TAFASITAMAB LENALIDOMIDE RITUXIMAB

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Rituximab and Abatacept May Contribute to Cancer Risk in Patients With Rheumatoid ArthritisRituximab and Abatacept May Contribute to Cancer Risk in Patients With Rheumatoid ArthritisThe biologic DMARDs rituximab and abatacept were associated with an increased risk for incident cancers in patients with RA in the first 2 years after the initiation of treatment.
Read more »

CTE Plus Family History of Mental Illness Raises Odds for AggressionCTE Plus Family History of Mental Illness Raises Odds for AggressionConcussion-related brain damage can combine with a family history of mental illness to make some athletes and military personnel prone to aggression and violence in middle age, a new study says.
Read more »

Therabody JetBoots Pro Plus Recovery Boots Review 2024Therabody JetBoots Pro Plus Recovery Boots Review 2024The Therabody JetBoots Pro Plus might be your missing link for recovery. Find out how these compression boots with red light therapy help with recovering.
Read more »

Astros Legend Predicted To Betray Houston For $120-Plus Million Free Agency DealAstros Legend Predicted To Betray Houston For $120-Plus Million Free Agency DealHouston Astros franchise legend Alex Bregman is being heavily connected to the Detroit Tigers in free agency this winter.
Read more »

Trump appoints ambassadors Kimberly Guilfoyle and Tom Barrack, plus 5 more picksTrump appoints ambassadors Kimberly Guilfoyle and Tom Barrack, plus 5 more picksHe named a total of seven appointments on Tuesday night via Truth Social.
Read more »

Delhi air pollution levels at 'severe plus', authorities sayDelhi air pollution levels at 'severe plus', authorities sayIndia's capital Delhi is experiencing one of its most polluted days this year.
Read more »



Render Time: 2025-02-14 20:14:56